The Clinical Relevance of Autoantibodies in Scleroderma PDF Print E-mail
Sunday, 11 July 2010 16:05
Khanh T Ho and John D Reveille
Published: 12 February 2003

Arthritis Res Ther 2003, 5:80-93 (DOI 10.1186/ar628)
© 2003 BioMed Central Ltd (Print ISSN 1478-6354; Online ISSN 1478-6362)

Scleroderma (systemic sclerosis) is associated with several autoantibodies, each of which is useful in the diagnosis of affected patients and in determining their prognosis. Anti-centromere antibodies (ACA) and anti-Scl-70 antibodies are very useful in distinguishing patients with systemic sclerosis (SSc) from healthy controls, from patients with other connective tissue disease, and from unaffected family members.

Whereas ACA often predict a limited skin involvement and the absence of pulmonary involvement, the presence of anti-Scl-70 antibodies increases the risk for diffuse skin involvement and scleroderma lung disease. Anti-fibrillarin autoantibodies (which share significant serologic overlap with anti-U3-ribonucleoprotein antibodies) and anti-RNA-polymerase autoantibodies occur less frequently and are also predictive of diffuse skin involvement and systemic disease. Anti-Th/To and PM-Scl, in contrast, are associated with limited skin disease, but anti-Th/To might be a marker for the development of pulmonary hypertension.

Other autoantibodies against extractable nuclear antigens have less specificity for SSc, including anti-Ro, which is a risk factor for sicca symptoms in patients with SSc, and anti-U1-ribonucleoprotein, which in high titer is seen in patients with SSc/systemic lupus erythematosus/polymyositis overlap syndromes. Limited reports of other autoantibodies (anti-Ku, antiphospholipid) have not established them as being clinically useful in following patients with SSc.

Login to download your own copy of the full and original review article from the link provided below

 
More articles :

» New Stem Cell Therapy To Help With Stubborn Wounds

The skin is the largest organ in the body with amazing healing powers, but what if your wounds didn't heal?That's the case for 6 million Americans suffering from chronic wounds that can take months, even years, to heal. Millions have no other choice...

» New Biomarker Predicts Poor Outcomes in Scleroderma

A novel biomarker may aid in establishing the prognosis of Systemic Sclerosis (Scleroderma), and particularly in predicting the most common lethal complications, an international group of researchers reported.Patients with Systemic Sclerosis who had...

» Preterm Delivery a Risk in Systemic Sclerosis

Many women with systemic sclerosis can have successful pregnancies, but the rates of preterm birth, low birth weight, and intrauterine growth restriction are approximately twice as high in these women compared to the general population of pregnant...

» Gene Profiling of Scleroderma Skin Reveals Robust Signatures of Disease...

Humphrey Gardner, Jeffrey R. Shearstone, Raj Bandaru, Tom Crowell, Matthew Lynes, Maria Trojanowska, Jaspreet Pannu, Edwin Smith, Stefania Jablonska, Maria Blaszczyk, Filemon K. Tan, and Maureen D. MayesARTHRITIS & RHEUMATISMVol. 54, No. 6, June...

» FDA Approves New Lupus Drug

The FDA has approved (Benlysta) for reducing disease activity in (SLE), making it the first new lupus drug in more than 50 years. Belimumab is a monoclonal antibody targeting the B-lymphocyte stimulator protein, called BLyS. It was co-developed by...

» New Genetic Path Targeted For Scleroderma Therapy

A genetic pathway previously known for its role in embryonic development and cancer has been identified as a target for systemic sclerosis, or scleroderma, therapy. The finding, discovered by a cross-disciplinary team led by John Varga, MD, John and...